Improving differential diagnosis of pituitary adenomas

References

• Aflorei ED, Korbonits M. Epidemiology and etiopathogenesis of pituitary adenomas. J Neurooncol 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 2013;16(4):545-53
   PubMed Web of Science ®Google Scholar
• Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010;72(3):377-82
   PubMed Web of Science ®Google Scholar
• Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004;101(3):613-19
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Trivellin G, Hernandez Ramirez LC, Korbonits M. Genetics of pituitary adenomas. Front Horm Res 2013;41:111-40
   PubMed Web of Science ®Google Scholar
• Daly AF, Beckers A. Update on the treatment of pituitary adenomas: familial and genetic considerations. Acta Clin Belg 2008;63(6):418-24
   PubMed Web of Science ®Google Scholar
• Daly AF, Tichomirowa MA, Beckers A. The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 2009;23(5):543-54
   PubMed Web of Science ®Google Scholar
• Martucci F, Trivellin G, Korbonits M. Familial isolated pituitary adenomas: an emerging clinical entity. J Endocrinol Invest 2012;35(11):1003-14
   PubMed Web of Science ®Google Scholar
• Vandeva S, Jaffrain-Rea ML, Daly AF, et al. The genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 2010;24(3):461-76
   PubMedGoogle Scholar
• Jaffrain-Rea M-L, Daly AF, Angelini M, et al. Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications. Expert Rev Endocrinol Metab 2011;6(2):195-214
   PubMedGoogle Scholar
• Korbonits M, Storr H, Kumar AV. Familial pituitary adenomas - who should be tested for AIP mutations? Clin Endocrinol (Oxf) 2012;77(3):351-6
   PubMedGoogle Scholar
• Beckers A, Rostomyan L, Daly AF. Overview of genetic testing in patients with pituitary adenomas. Ann Endocrinol (Paris) 2012;73(2):62-4
   PubMedGoogle Scholar
• Mete O, Asa SL. Clinicopathological correlations in pituitary adenomas. Brain Pathol 2012;22(4):443-53
   PubMed Web of Science ®Google Scholar
• Mete O, Asa SL. Therapeutic implications of accurate classification of pituitary adenomas. Semin Diagn Pathol 2013;30(3):158-64
   PubMedGoogle Scholar
• Trouillas J, Roy P, Sturm N, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol (Berl) 2013;126(1):123-35
   PubMed Web of Science ®Google Scholar
• Xekouki P, Azevedo M, Stratakis CA. Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways. Expert Rev Endocrinol Metab 2010;5(5):697-709
   PubMedGoogle Scholar
• Stratakis CA, Tichomirowa MA, Boikos S, et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet 2010;78(5):457-63
   PubMed Web of Science ®Google Scholar
• Trouillas J, Labat-Moleur F, Sturm N, et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 2008;32(4):534-43
   PubMedGoogle Scholar
• Toledo SP, Lourenco DM Jr, Toledo RA. A differential diagnosis of inherited endocrine tumors and their tumor counterparts. Clinics 2013;68(7):1039-56
   PubMedGoogle Scholar
• Delemer B. MEN 1 and pituitary adenomas. Ann Endocrinol (Paris) 2012;73(2):59-61
   PubMedGoogle Scholar
• Syro LV, Scheithauer BW, Kovacs K, et al. Pituitary tumors in patients with MEN1 syndrome. Clinics 2012;1(Suppl 67):43-8
   Google Scholar
• Toledo RA, Lourenco DM Jr, Coutinho FL, et al. Novel MEN1 germline mutations in Brazilian families with multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 2007;67(3):377-84
   PubMedGoogle Scholar
• Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012;97(9):2990-3011
   PubMed Web of Science ®Google Scholar
• Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86(12):5658-71
   PubMed Web of Science ®Google Scholar
• Lourenco DM Jr, Toledo RA, Coutinho FL, et al. The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1. Clinics 2007;62(4):465-76
   PubMedGoogle Scholar
• Beckers A, Aaltonen LA, Daly AF, Karhu A. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 2013;34(2):239-77
   PubMed Web of Science ®Google Scholar
• Daly AF, Jaffrain-Rea ML, Ciccarelli A, et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 2006;91(9):3316-23
   PubMed Web of Science ®Google Scholar
• Daly AF, Tichomirowa MA, Beckers A. Genetic, molecular and clinical features of familial isolated pituitary adenomas. Horm Res 2009;2(Suppl 71):116-22
   Google Scholar
• Daly AF, Tichomirowa MA, Petrossians P, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 2010;95(11):E373-83
   PubMed Web of Science ®Google Scholar
• Tichomirowa MA, Barlier A, Daly AF, et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 2011;165(4):509-15
   PubMed Web of Science ®Google Scholar
• Toledo RA, Lourenco DM Jr, Liberman B, et al. Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. J Clin Endocrinol Metab 2007;92(5):1934-7
   PubMed Web of Science ®Google Scholar
• Toledo RA, Lourenco DM Jr, Toledo SP. Familial isolated pituitary adenoma: evidence for genetic heterogeneity. Front Horm Res 2010;38:77-86
   PubMedGoogle Scholar
• Rothenbuhler A, Stratakis CA. Clinical and molecular genetics of Carney complex. Best Pract Res Clin Endocrinol Metab 2010;24(3):389-99
   PubMedGoogle Scholar
• Salpea P, Horvath A, London E, et al. Deletions of the PRKAR1A locus at 17q24.2-q24.3 in carney complex: genotype-phenotype correlations and implications for genetic testing. J Clin Endocrinol Metab 2014;99(1):E183-8
   Google Scholar
• Salpea P, Stratakis CA. Carney complex and McCune Albright syndrome: an overview of clinical manifestations and human molecular genetics. Mol Cell Endocrinol 2014;386(1-2):85-91
   PubMed Web of Science ®Google Scholar
• Courcoutsakis NA, Tatsi C, Patronas NJ, et al. The complex of myxomas, spotty skin pigmentation and endocrine overactivity (Carney complex): imaging findings with clinical and pathological correlation. Insights Imaging 2013;4(1):119-33
   PubMedGoogle Scholar
• Salenave S, Boyce AM, Collins MT, Chanson P. Acromegaly and McCune-Albright syndrome. J Clin Endocrinol Metab 2014. [Epub ahead of print]
   Google Scholar
• Scheithauer BW, Horvath E, Abel TW, et al. Pituitary blastoma: a unique embryonal tumor. Pituitary 2012;15(3):365-73
   PubMed Web of Science ®Google Scholar
• Bauer AJ, Stratakis CA. The lentiginoses: cutaneous markers of systemic disease and a window to new aspects of tumourigenesis. J Med Genet 2005;42(11):801-10
   PubMedGoogle Scholar
• Lucas JW, Zada G. Imaging of the pituitary and parasellar region. Semin Neurol 2012;32(4):320-31
   PubMed Web of Science ®Google Scholar
• Rand T, Lippitz P, Kink E, et al. Evaluation of pituitary microadenomas with dynamic MR imaging. Eur J Radiol 2002;41(2):131-5
   PubMedGoogle Scholar
• Pinker K, Ba-Ssalamah A, Wolfsberger S, et al. The value of high-field MRI (3T) in the assessment of sellar lesions. Eur J Radiol 2005;54(3):327-34
   PubMed Web of Science ®Google Scholar
• Portocarrero-Ortiz L, Bonifacio-Delgadillo D, Sotomayor-Gonzalez A, et al. A modified protocol using half-dose gadolinium in dynamic 3-Tesla magnetic resonance imaging for detection of ACTH-secreting pituitary tumors. Pituitary 2010;13(3):230-5
   PubMedGoogle Scholar
• Heck A, Ringstad G, Fougner SL, et al. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf) 2012;77(1):72-8
   PubMed Web of Science ®Google Scholar
• Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993;33(4):610-17; discussion 617-618
   PubMed Web of Science ®Google Scholar
• Boxerman JL, Rogg JM, Donahue JE, et al. Preoperative MRI evaluation of pituitary macroadenoma: imaging features predictive of successful transsphenoidal surgery. AJR Am J Roentgenol 2010;195(3):720-8
   PubMedGoogle Scholar
• Cao L, Chen H, Hong J, et al. Magnetic resonance imaging appearance of the medial wall of the cavernous sinus for the assessment of cavernous sinus invasion by pituitary adenomas. J Neuroradiol 2013;40(4):245-51
   PubMedGoogle Scholar
• Stofko DL, Nickles T, Sun H, Dehdashti AR. The value of immediate postoperative MR imaging following endoscopic endonasal pituitary surgery. Acta Neurochir (Wien) 2014;156(1):133-40; discussion 140
   PubMedGoogle Scholar
• Mete O, Ezzat S, Asa SL. Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 2012;49(2):R69-78
   PubMed Web of Science ®Google Scholar
• Sav A, Rotondo F, Syro LV, et al. Biomarkers of pituitary neoplasms. Anticancer Res 2012;32(11):4639-54
   PubMed Web of Science ®Google Scholar
• Salehi F, Agur A, Scheithauer BW, et al. Ki-67 in pituitary neoplasms: a review--part I. Neurosurgery 2009;65(3):429-37. discussion 437
   PubMed Web of Science ®Google Scholar
• Heaney AP. Pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab 2011;96(12):3649-60
   PubMed Web of Science ®Google Scholar
• Ezzat S, Zheng L, Asa SL. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol Endocrinol 2004;18(10):2543-52
   PubMed Web of Science ®Google Scholar
• Hussaini IM, Trotter C, Zhao Y, et al. Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am J Pathol 2007;170(1):356-65
   PubMed Web of Science ®Google Scholar
• Fedele M, Pierantoni GM, Visone R, Fusco A. Critical role of the HMGA2 gene in pituitary adenomas. Cell Cycle 2006;5(18):2045-8
   PubMed Web of Science ®Google Scholar
• Ezzat S, Asa SL. The emerging role of the Ikaros stem cell factor in the neuroendocrine system. J Mol Endocrinol 2008;41(2):45-51
   PubMedGoogle Scholar
• Qian ZR, Asa SL, Siomi H, et al. Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod Pathol 2009;22(3):431-41
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Kasuki L, Denes J, et al. MicroRNAs: suggested role in pituitary adenoma pathogenesis. J Endocrinol Invest 2013;36(10):889-95
   PubMedGoogle Scholar
• Sivapragasam M, Rotondo F, Lloyd RV, et al. MicroRNAs in the human pituitary. Endocr Pathol 2011;22(3):134-43
   PubMed Web of Science ®Google Scholar
• Lloyd R, Kovacs K, Young WFJ, et al. Pituitary tumors: Introduction. In: De Lellis RA, Lloyd RV, Heitz PU, Eng C, editors. World Health Organization classification of tumours: pathology and genetics of tumours of endocrine organs. IARC Press; Lyon, France: 2004;11-13
   Google Scholar
• Asa SL. Tumors of the pituitary gland. Armed Forces Institute of Pathology; Washington, DC, USA: 2011
   Google Scholar
• Osamura RY, Kajiya H, Takei M, et al. Pathology of the human pituitary adenomas. Histochem Cell Biol 2008;130(3):495-507
   PubMed Web of Science ®Google Scholar
• Asa SL, Ezzat S. The pathogenesis of pituitary tumors. Annu Rev Pathol 2009;4:97-126
   PubMed Web of Science ®Google Scholar
• Raverot G, Jouanneau E, Trouillas J. Clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur J Endocrinol 2014;170(4):R121-32
   PubMed Web of Science ®Google Scholar
• Nose V, Ezzat S, Horvath E, et al. Protocol for the examination of specimens from patients with primary pituitary tumors. Arch Pathol Lab Med 2011;135(5):640-6
   PubMedGoogle Scholar
• Kiseljak-Vassiliades K, Shafi S, Kerr JM, et al. Clinical implications of growth hormone-secreting tumor subtypes. Endocrine 2012;42(1):18-28
   PubMedGoogle Scholar
• Lopes MB. Growth hormone-secreting adenomas: pathology and cell biology. Neurosurg Focus 2010;29(4):E2
   PubMed Web of Science ®Google Scholar
• Chinezu L, Vasiljevic A, Jouanneau E, et al. Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Hum Pathol 2014;45(1):71-7
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev 2011;32(2):247-71
   PubMed Web of Science ®Google Scholar
• Mori R, Inoshita N, Takahashi-Fujigasaki J, et al. Clinicopathological features of growth hormone-producing pituitary adenomas in 242 acromegaly patients: classification according to hormone production and cytokeratin distribution. ISRN Endocrinol 2013;2013:723432
   PubMedGoogle Scholar
• Casarini AP, Jallad RS, Pinto EM, et al. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary 2009;12(4):297-303
   PubMed Web of Science ®Google Scholar
• Fougner SL, Casar-Borota O, Heck A, et al. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf) 2012;76(1):96-102
   PubMed Web of Science ®Google Scholar
• Gola M, Bonadonna S, Mazziotti G, et al. Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 2006;29(1):86-93
   PubMed Web of Science ®Google Scholar
• Delgrange E, Daems T, Verhelst J, et al. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 2009;160(5):747-52
   PubMedGoogle Scholar
• Maiter D, Delgrange E. The challenges in managing giant prolactinomas. Eur J Endocrinol 2014. [Epub ahead of print]
   Google Scholar
• Horvath E, Kovacs K, Singer W, et al. Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer 1981;47(4):761-71
   PubMedGoogle Scholar
• Lim JS, Ku CR, Lee MK, et al. A case of fugitive acromegaly, initially presented as invasive prolactinoma. Endocrine 2010;38(1):1-5
   PubMedGoogle Scholar
• Saeger W, Ludecke DK, Buchfelder M, et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 2007;156(2):203-16
   PubMed Web of Science ®Google Scholar
• Malchiodi E, Profka E, Ferrante E, et al. Thyrotropin-secreting pituitary adenomas: outcome of pituitary surgery and irradiation. J Clin Endocrinol Metab 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• George DH, Scheithauer BW, Kovacs K, et al. Crooke’s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 2003;27(10):1330-6
   PubMed Web of Science ®Google Scholar
• Kovacs K, Diep CC, Horvath E, et al. Prognostic indicators in an aggressive pituitary Crooke’s cell adenoma. Can J Neurol Sci 2005;32(4):540-5
   PubMedGoogle Scholar
• Rotondo F, Cusimano M, Scheithauer BW, et al. Atypical, invasive, recurring Crooke cell adenoma of the pituitary. Hormones (Athens) 2012;11(1):94-100
   PubMedGoogle Scholar
• Melcescu E, Gannon AW, Parent AD, et al. Silent or subclinical corticotroph pituitary macroadenoma transforming into Cushing disease: 11-year follow-up. Neurosurgery 2013;72(1):E144-6
   Google Scholar
• Moshkin O, Syro LV, Scheithauer BW, et al. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy. Hormones (Athens) 2011;10(2):162-7
   PubMedGoogle Scholar
• Jahangiri A, Wagner JR, Pekmezci M, et al. A comprehensive long-term retrospective analysis of silent corticotrophic adenomas versus hormone-negative adenomas. Neurosurgery 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Psaras T, Honegger J, Buslei R, et al. Atypical type II silent corticotrophic adenoma developing into Cushing’s disease upon second recurrence. Exp Clin Endocrinol Diabetes 2007;115(9):610-15
   PubMedGoogle Scholar
• Cho HY, Cho SW, Kim SW, et al. Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf) 2010;72(5):648-53
   PubMedGoogle Scholar
• Cooper O, Melmed S. Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab 2012;26(4):447-60
   PubMedGoogle Scholar
• Erickson D, Scheithauer B, Atkinson J, et al. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol (Oxf) 2009;71(1):92-9
   PubMed Web of Science ®Google Scholar
• Horvath E, Kovacs K, Smyth HS, et al. Silent adenoma subtype 3 of the pituitary--immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 2005;29(6):511-24
   PubMed Web of Science ®Google Scholar